A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...

(C) PFS and (D) OS in class 2 versus other MAP2K1 mutant tumors in patients treated with MEK inhibitor–containing treatment regimens. (E) PFS and (F) OS in patients who experienced a response to MAPK ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

The Janus kinase inhibitor baricitinib, in combination with narrowband ultraviolet B therapy, improved vitiligo, according to ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...